Agammaglobulinemia (Review) D81.4

Last updated on: 03.07.2022

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Primary agammaglobulinemia is either an X-linked recessive or an autosmal recessive/dominant inherited immunodeficiency characterized by very low or absent serum antibodies and low or absent circulating B cells due to early blockade of B cell development. Affected individuals develop severe infections in the first few years of life.

The most common form of primary agammaglobulinemia is X-linked agammaglobulinemia (AGMX1, XLA; 300755), also known as Bruton disease, which is caused by a mutation in the BTK gene (300300). AGMX1 accounts for 85 to 95% of male patients with the characteristic findings (Ferrari et al., 2007).

An autosomal recessive inheritance in agammaglobulinemias results in a phenotype similar to that seen in the X-linked form. This phenoytp has been observed in a small number of families and accounts for up to 15% of patients with agammaglobulinemia (Ferrari et al., 2007).

ClassificationThis section has been translated automatically.

Primary antibody deficiency syndromes involve a genetic deficiency of immunoglobulins. Primary immunodeficiencies leading to antibody deficiency syndrome (AMS) include:

  • AGMX1 (agammaglobulinemia, X-LINKED; XLA; Bruton syndrome; agammaglobulinemia type Bruton; mutations on the BTK gene at gene locus Xq22.
  • AGM1(agammaglobulinemia type 1, autosomal recessive), mutations in IGHM gene at 14q32.33.
  • AGM2 (agammaglobulinemia type 2, autosomal recessive), mutations in the IGLL1 gene at 22q11.23
  • AGM3(agammaglobulinemia type 3, autosomal recessive), mutations in the CD79A gene at 19q13.2[5]
  • AGM4(agammaglobulinemia type 4, autosomal recessive), mutations in BLNK gene at 10q24.1
  • AGM5 (agammaglobulinemia type 5, autosomal dominant), mutations in LRRC8A gene at 9q34.11
  • AGM6(agammaglobulinemia type 6, autosomal recessive), mutations in CD79B gene at 17q23.3
  • AGM9(agammaglobulinemia 9, autosomal recessive), mutation in SLC39A7

Hypogammaglobulinemia is also associated with the following diseases:

LiteratureThis section has been translated automatically.

  1. Cellier C et al (2000) Regional enteritis associated with enterovirus in a patient with X-linked agammaglobulinemia. N Engl J Med 342: 1611-1612
  2. Conley ME, Howard V (2002) Clinical findings leading to the diagnosis of X-linked agammaglobulinemia. J Pediatr 141: 566-571.
  3. Fancher KMet al.(2020) Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management. Cancer Chemother Pharmacol 86: 507-515.
  4. Howard V et al (2003) Stem cell transplants for patients with X-linked agammaglobulinemia. Clin Immunol 107: 98-102
  5. Jo EK et al (2003) Identification of mutations in the Bruton's tyrosine kinase gene, including a novel genomic rearrangements resulting in large deletion, in Korean X-linked agammaglobulinemia patients. J Hum Genet 48: 322-326

Last updated on: 03.07.2022